Emerging Novel Therapies in Bladder Cancer

home / publications / supplements / emerging-novel-therapies-in-bladder-cancer
Neal D. Shore, MD, FACS

Dr Shore on the Rationale for the Duravelo-2 Trial in Metastatic Urothelial Cancer

Neal Shore, MD, FACS
November 8th 2024
Video

Neal D. Shore, MD, FACS, discusses the Duravelo-1 and Duravelo-2 trials investigating zelenectide pevedotin in metastatic urothelial carcinoma.

Neal Shore, MD, FACS, of Carolina Urologic Research Center

First-in-Class Bicycle Toxin Conjugate Targeting Nectin-4 Generates Excitement in Urothelial Carcinoma

Megan Hollasch
October 23rd 2024
Article

Oncologists detail how zelenectide pevedotin, which is under evaluation in the Duravelo-2 trial, could fill an unmet need in metastatic urothelial carcinoma.

Srikala Sridhar, MD, MSc, FRCPC

Dr Sridhar on the Use of Zelenectide Pevedotin in Locally Advanced or Metastatic Urothelial Cancer

Srikala Sridhar, MD, MSc, FRCPC
October 11th 2024
Video

Srikala Sridhar, MD, MSc, FRCPC, discusses the unique application of zelenectide pevedotin, which targets nectin-4 in locally advanced or metastatic urothelial cancer.

Terence Friedlander, MD

Zelenectide Pevedotin Shows Early Promise as Less Toxic Alternative to Standard Regimens in Bladder Cancer

Courtney Flaherty
September 27th 2024
Article

Terence Friedlander, MD, spotlights emerging agents of interest in advanced bladder cancer, including the Nectin-4–targeted therapy zelenectide pevedotin.

Terence W. Friedlander, MD

Dr Friedlander on the Duravelo-2 Trial for Advanced or Metastatic Urothelial Cancer

Terence Friedlander, MD
August 8th 2024
Video

Terence W. Friedlander, MD, discusses the investigation of BT8009 in the Duravelo-2 study in patients with advanced or metastatic urothelial cancer.